Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D08HRJ
|
||||
Former ID |
DAP000337
|
||||
Drug Name |
Cyclizine
|
||||
Synonyms |
Ciclizina; Cyclizinum; Emoquil; Marezine; Nautazine; Valoid; Wellcome; Cyclizine chloride; Cyclizine hydrochloride; Marezine hydrochloride; BW 47-83; Ciclizina [INN-Spanish]; Cyclizine (INN); Cyclizinum [INN-Latin]; Emoquil (TN); Marezine (TN); Marzine (TN); Ne-devomit; Neo-devomit; Reis-fit; Valoid (TN); Wellcome preparation 47-83; Wellcome prepn 47-83; Cyclizine [INN:BAN:DCF]; Wellcome prepn. 47-83; N-Benzhydryl-N'-methylpiperazine; N-Methyl-N'-benzhydrylpiperazine; N-Methyl-N'-benzyhydrylpiperazine; (+-)-1-diphenylmethyl-4-methylpiperazine; (-)-1-Diphenylmethyl-4-methylpiperazine; (N-Benzhydryl)(N'-methyl)diethylenediamine; 1-(Diphenylmethyl)-4-methylpiperazine; 1-Benzhydryl-4-methylpiperazin; 1-Benzhydryl-4-methylpiperazine; 1-Diphenylmethyl-4-methylpiperazine
|
||||
Drug Type |
Small molecular drug
|
||||
Therapeutic Class |
Antiemetics
|
||||
Company |
Seatrace Pharmaceuticals
|
||||
Structure |
Download2D MOL |
||||
Formula |
C18H22N2
|
||||
InChI |
InChI=1S/C18H22N2/c1-19-12-14-20(15-13-19)18(16-8-4-2-5-9-16)17-10-6-3-7-11-17/h2-11,18H,12-15H2,1H3
|
||||
InChIKey |
UVKZSORBKUEBAZ-UHFFFAOYSA-N
|
||||
CAS Number |
CAS 82-92-8
|
||||
PubChem Compound ID | |||||
PubChem Substance ID |
9147, 87441, 7625538, 7979006, 8154360, 10536697, 11112316, 11342188, 11362371, 11363748, 11366310, 11368872, 11371415, 11373948, 11377034, 11466538, 11467658, 11484923, 11486096, 11487773, 11488990, 11490184, 11492020, 11494668, 15197232, 17397725, 26611677, 26679882, 26747952, 26747953, 29225675, 46506232, 47440552, 47662546, 47960014, 47960015, 48035410, 48035411, 48185245, 48415824, 49698831, 50012930, 56394858, 57323665, 80297363, 85209423, 85787928, 85789538, 92123944, 92307358
|
||||
ChEBI ID |
ChEBI:3994
|
||||
SuperDrug ATC ID |
R06AE03
|
||||
SuperDrug CAS ID |
cas=000082928
|
||||
Target and Pathway | |||||
Target(s) | Histamine H1 receptor | Target Info | Antagonist | [535368], [535716], [537890] | |
PANTHER Pathway | Histamine H1 receptor mediated signaling pathway | ||||
References | |||||
Ref 538421 | FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 009495. | ||||
Ref 542159 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7151). | ||||
Ref 535368 | Comparison of cyclizine and ondansetron for the prevention of postoperative nausea and vomiting in laparoscopic day-case gynaecological surgery. Anaesthesia. 2002 Jan;57(1):61-5. | ||||
Ref 535716 | Histamine H1-receptor antagonists, promethazine and homochlorcyclizine, increase the steady-state plasma concentrations of haloperidol and reduced haloperidol. Ther Drug Monit. 2003 Apr;25(2):192-6. | ||||
Ref 537890 | Synthesis and combined H1-/H2 antagonist activity of mepyramine, pheniramine and cyclizine derivatives with cyanoguanidine, urea and nitroethenediamine partial structures. Arch Pharm (Weinheim). 1994Jul;327(7):455-62. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.